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We read with great interest the Editorial from Moghnieh 
et al. on the EMPIRICUS trial and antifungal use in 
intensive care unit (ICU) (1). Authors described nicely 
the trial and some background evidence on untargeted 
antifungal treatment in non-neutropenic critically ill 
patients in ICU (2,3). However, we believe that some points 
may be further clarified. First, it may be useful to cite the 
study from Knitsch et al. among those evaluating empiric 
antifungal treatment in ICU (4). Knitsch et al. enrolled 
252 critically ill patients with localized/generalized intra-
abdominal infection either of community or of nosocomial 
origin requiring emergency surgery. They were randomized 
to receive micafungin or placebo. Interestingly, the study 
was unable to provide any significant difference in terms 
of invasive candidiasis or mortality between groups. The 
absence of difference in invasive fungal infections (IFI) is in 
contrast with the results from Timsit et al. and the overall 
evidence from Cochrane systematic review (5,6). The 
evidence from this trial may partially overcome, for a global 
overview, the limited number of surgical patients enrolled 
in the EMPIRICUS trial. Second, Moghnieh et al. stated 
that the antifungal treatment of the trial from Timsit et al. 
should be considered as preemptive. Although it may be 
useless to discuss about definitions (7), the most appropriate 
definition seems to be “empiric” because the trial enrolled 
septic patients with multiple organ failure. In this case, 
the administration of antifungal agents depicts an empiric 
treatment, even though the selected population had a high 
risk of IFI based on known risk factors (i.e., broad spectrum 
antibiotic therapy, multi-site Candida colonization) (8). The 
enrolled population had a high level of critical illness (at 
the admission mean SOFA score 8, mean SAPS II 48) and 
this may lead to consider the timing of empirical antifungal 
treatment as “too late”, potentially explaining the lack of 
effect on mortality (9). Third, other explanations about 
the paradoxical association between the reduced incidence 
of IFI and the absence of effect on mortality observed in 
the EMPIRICUS and other major trials on antifungal 
treatment may be interesting for the readers. In clinical 
words, many non-neutropenic critically ill patients with IFI 
die despite of effective antifungal agents, which do their job 
leading to a reduction in identifiable fungi in sterile sites 
by microbiological cultures. Nowadays, there is evidence 
supporting altered immunological functions in patients 
with IFI, definable as “immunoparalysis”. Interestingly, 
this occurs in patients without neutropenia or other 
known factors classically describing the clinical picture 
of immunosuppression. It may be speculated that the 
impaired immunological response has a causative role on 
the lack of benefit in terms of mortality in patients treated 
with highly effective antifungal drugs (10). An insight for 
future research might be to evaluate immunomodulation 
therapy for patients at risk of IFI or with established fungal 
infection.
Lastly, we have now established evidence to support 
the fact that classic “old” antifungal strategies, such as 
prophylaxis and empiric treatment, are not associated with 
improved survival in critically ill non-neutropenic patients. 
Moreover, we have also evidence describing the increasing 
rate of resistance to antifungals, even echinocandins, when 
used widely (9). We agree with Moghnieh et al. on the 
need of a better selection of patients and a better timing 
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for antifungal treatment. Biomarkers, such as β-D-glucan, 
alternative techniques for identification (e.g., polymerase 
chain reactions assays, T2, mass spectrometry—MALDI-
TOF), risk factors, prediction scores, combined together, 
might be a good way to improve our antifungal strategies. 
Before starting to evaluate new therapeutic algorithms 
we should focus on data trying to interpret them and 
understand what they are telling us. Concerning antifungal 
treatment, it is simple possible that, as clinicians, we have 
to do what guidelines suggests based on “good clinical 
judgment”, knowing that, lack of effect is behind the corner.
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